Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: Role of vascular NAD(P)H oxidase

Journal of the American Society of Nephrology

Volumn 14, Issue SUPPL. 3, 2003, Pages

  Inoguchi, Toyoshi ^a,b   Sonta, Toshiyo ^a   Tsubouchi, Hirotaka ^a   Etoh, Takashi ^a   Kakimoto, Maiko ^a   Sonoda, Noriyuki ^a   Sato, Naoichi ^a   Sekiguchi, Naotaka ^a   Kobayashi, Kunihisa ^a   Sumimoto, Hideki ^b   Utsumi, Hideo ^a   Nawata, Hajime ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ALPHA TOCOPHEROL; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; CALPHOSTIN C; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENYLIODONIUM SALT; ENZYME INHIBITOR; FATTY ACID; GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; OLMESARTAN; PHORBOL 13 ACETATE 12 MYRISTATE; PITAVASTATIN; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C INHIBITOR; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROTENONE; RUBOXISTAURIN;

ANIMAL MODEL; ANIMAL TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ELECTRON SPIN RESONANCE; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; VASCULAR ENDOTHELIUM;

EID: 18144447696     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
3. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988
4. Greene DA, Lattimer SA, Sima AA: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316: 599-606, 1987
5. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991
6. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288: 2579-2588, 2002
7. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89: 11059-11063, 1992
8. Inoguchi T, Xia P, Kunisaki M, Higashi S, Feener EP, King GL: Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 267: E369-E379, 1994
9. Shiba T, Inoguchi T, Sportsman JR, Heat WF, Bursell S, King GL: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 265: E783-E793, 1993
10. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43: 1122-1129, 1994
11. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Invest 83: 1667-1675, 1989
12. Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR, Turk J: Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 87: 31-38, 1991
13. Hinokio Y, Suzuki S, Hirai M, Chiba M, Hirai A, Toyota T: Oxidative DNA damage in diabetes mellitus: Its association with diabetic complications. Diabetologia 42: 995-998, 1999
14. Ha H, Kim C, Son Y, Chung MH, Kim KH: DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria. Free Radic Biol Med 16: 271-274, 1994
15. Sano T, Umeda F, Hashimoto T, Nawata H, Utsumi H: Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 41: 1355-1360, 1998
16. Kakimoto T, Inoguchi T, Sonta T, HY Yu, Imamura M, Etoh T, Hashimoto T, Nawata H: Accumulation of 8-hydroxy-2′-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes 51: 1588-1595, 2002
17. Mullarkey CJ, Edelstein D, Brownlee M: Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173: 932-939, 1990
18. Williamson JR, Chang K, Fragos M, Hsan KS, Ido Y, Kawamura T, Nyengaard JR, van den Eden M, Kilo C, Tilton RG: Hyperglycemic pseudhypoxia and diabetic complications. Diabetes 42: 801-813, 1993
19. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404: 787-790, 2000
20. Mohazzab KM, Kaminski PM, Wolin MS: NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 266: H2568-H2572, 1994
21. Griendling KK, Minieri CA, Ollerenshaw JD, Alexande RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994
22. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NAD/NADPH oxidase activation. J Clin Invest 97: 1916-1923, 1996
23. Ushio-Fukai M, Zafari AM, Fukui T, Ishizuka N, Griendling KK: p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271: 23317-23321, 1996
24. Warnholtz A, Nickenig G, Schulz E, Machazina R, Brazen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm MD, Meinertz T, Munzel T: Increased NADH Oxidase-mediated superoxide production in the early stages of atherosclerosis. Circulation 99: 2027-2033, 1999
25. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M: Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100: 1494-1498, 1999
26. Barry-Lane P-A, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ETH, Runge MSJ: p47phox is required for atherosclerotic lesion progression in Apo E-/- mice. J Clin Invest 108: 1513-1522, 2001
27. Sorescu D, Weiss D, Lassegue B, Clempus R, Szocs L, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling, KK: Superoxide production and expression of Nox family protein in human atherosclerosis. Circulation 105: 1429-1435, 2002
28. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers IVQ, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK: p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997
29. Tesfamariam B, Brown ML, Cohen RA: Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87: 1643-1648, 1991
30. Studor PK, Craven PA, DeRubertis FR: Role of protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 42: 118, 1993
31. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272: 728, 1996
32. Kuroki T, Inoguchi T, Umeda F, Ueda F, Nawata H: High glucose induces alteration of gap junction permeability and phosphorylation of connexin-43 in cultured aortic smooth muscle cells. Diabetes 47: 931-936, 1998
33. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCb inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439-447, 2000
34. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939-1945, 2000
35. Kobayashi T, Seguchi H: Novel insight into current models of NADPH oxidase regulation, assembly and localization in human polymorphonuclear leukocytes. Histol Histopathol 14: 1295-1308, 1999
36. Kuroki T, Inoguchi T, Umeda F, Nawata H: Effect of eicosapentaenoic acid on glucose-induced diacylglycerol synthesis in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun 247: 473-477, 1998
37. Yu HY, Inoguchi T, Kakimoto M, Nakashima N, Imamura M, Hashimoto T, Umeda F, Nawata H: Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase C activity in cultured aortic smooth muscle cells. Diabetologia 44: 614-620, 2001
38. Bulow J, Madsen, Hojgaard L: Reversibility of the effect on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest 50: 291-296, 1990
39. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatty acid level impair endothelium-dependent vasodilation. J Clin Invest 100: 1230-1239, 1997
40. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RAK, Warnholtz A, Meinertz T, Griendling KK, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: e14-e22, 2001
41. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, Kim CD: Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51: 522-527, 2002
42. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus. Circulation 105: 1656-1662, 2002
43. 2, vascular endothelial growth factor in the retina of the BBZ/Wor diabetic rat. Free Radical Biol Med 28: 91-101, 2000
44. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimot H, Nawata, H: Increased expression of NAD(P)H oxidase subunits, NOX4 and p22pox, in kidney of diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 2003, in press
45. Utsumi H, Muto E, Masuda S, Hamada A: In vivo ESR measurement of free radicals in whole mice. Biochem Biophys Res Commun 172: 1342-1348, 1990
46. Swartz HM: Principles of the metabolism of nitroxides and their implications for spin trapping. Free Radic Res Commun 9: 399-405, 1990
47. Miura Y, Anzai K, Urano S, Ozawa T: In vivo electron paramagnetic resonance studies on oxidative stress caused by X-irradiation in whole mice. Free Radic Biol Med 23: 533-540, 1997
48. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69, 2000
49. Vecchione C, Brandes RP: Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91: 173-179, 2002
50. Lam KS, Cheng IK, Janus ED, Pang RW: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38: 604-609, 1995
51. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20: 1891-1895, 1997
52. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and Micro-HOPE substudy. Lancet 355: 253-259, 2000
53. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
54. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar SN: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
55. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB. Kidney Int 61: 186-194, 2002